The problem with advances in cancer is that they tend to show up the exaggerations of previous claims. And here we have it again: In the ‘world’s largest ever screening trial led by UCL,
The new method uses a statistical calculation to interpret changing levels in women’s blood of a protein called CA125, which is linked to ovarian cancer. This gives a more accurate prediction of a woman’s individual risk of developing cancer, compared to the conventional screening method, which uses a fixed ’cut-off’ point for CA125.
The new method detected cancer in 86% of unlike the current test which would have identified fewer than half of these women (41% or 48% respectively).